Body fatness and bevacizumab-based therapy in metastatic colorectal cancer.
Renehan
Andrew G
AG
Department of Surgery, University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. arenehan@picr.man.ac.uk
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015992:Body Mass Index; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D009765:Obesity / Q000150:complications* / Q000378:metabolism; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab